Timothy Rodgers
Dermatology · Frisco, TXNPI 1255395067
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 476 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations.
Across 476 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Pfizer$2K
- Amgen$786
- Lilly USA, LLC$783
- Novartis$666
- Johnson & Johnson$619
- plus $4K from 34 others
Across 329 payments — averaging $2964.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$377K
- LEO Pharma AS$182K
- Incyte Corporation$117K
- Takeda Pharmaceuticals U.S.A., Inc.$110K
- Pfizer$100K
- Arcutis Biotherapeutics, Inc.$41K
- plus $48K from 3 others
What the payments were for
- Travel & lodging$9708%
- Food & beverage$10,61191%
- Education$1121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,692 in reported general payments places this provider in the 75th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 72 | $3,869 |
| Triamcinolone Acetonide | 110 | $1,053 |
| Ketoconazole | 57 | $767 |
| Doxycycline Hyclate | 11 | $267 |
| ValacyclovirValacyclovir Hcl | 12 | $139 |
| Hydrocortisone | 25 | $118 |
| Prednisone | 14 | $22 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Frisco
- Dornechia CarterFrisco$111K
- Edward LainAustin$2.5M
- William CragunSan Antonio$2.2M
- Alpesh DesaiHouston$1.6M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
- Emily BeckerSan Antonio$1.2M
- Ross RaduskyDallas$1.2M
- Joseph MerolaDallas$1.2M
- Daniel CarrascoAustin$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.